Sign up
ROIV

Roivant Sciences Ltd (NASDAQ: ROIV)

Healthcare · Biotechnology

——

Quote unavailable · Price data is temporarily unavailable.

Set alert

The Quantellect read. The borrow fee is 0.41%. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumNeutral

RSI (14) 59.1 (overbought above 70, oversold below 30)

Trend—

—

Short interest7.8% of float

FINRA settlement Oct 30, 2026

ROIV price chart

Price — · As of —

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open—
Previous close—
Day range—
52-week range—
Volume—
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

ROIV · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 17

Insufficient data · Observed Sep 25, 2026, 12:33 PM ET

Squeeze27Idle—
Social Pulse

2 mentions in 24h

How the scores work →

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

— · Analyst consensus not available

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q2 2026−$0.45−$0.27—
Q1 2026−$0.36−$0.26—
Annual 2026—−$0.54—
Q3 2025—−$0.38—
Q2 2025—−$0.17—
Q1 2025—−$0.33—
Annual 2025—−$0.24—
Q3 2024−$0.24$0.23—

Smart-money activity

— · Smart-money activity not available

All smart-money activity →

News and press releases

All ROIV news →

Company profile

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the

CEO
—
Headquarters
London, United Kingdom
Employees
721
IPO date
Oct 1, 2021
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.